Download PDF
Semin Neurol 2019; 39(05): 589-595
DOI: 10.1055/s-0039-1693005
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Guillain–Barre Syndrome

Elia Malek
1   Department of Neurology, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon
,
Johnny Salameh 
1   Department of Neurology, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon
› Author Affiliations
Further Information

Publication History

Publication Date:
22 October 2019 (online)

    Permissions and Reprints

Abstract

Guillain–Barre syndrome (GBS) is the leading cause of acute paralysis that can potentially affect all of the human population. GBS is believed to be an immune-mediated disease, possibly triggered by a recent infection, and driven by an immune attack targeting the peripheral nervous system. GBS can be divided into several subtypes depending on the phenotype, pathophysiology, and neurophysiological features. Unfortunately, morbidity and mortality rates are still high despite the current understanding of the pathophysiology and available treatment options. Additional research is still needed to shed more light into the pathogenesis for a better understanding and treatment of this condition.

Keywords

Guillain–Barre syndrome - acute inflammatory demyelinating polyneuropathy - acute motor axonal polyneuropathy - Miller–Fisher syndrome
 

  • References

  • 1 Walusinski O. Pioneering the concepts of stereognosis and polyradiculoneuritis: Octave Landry (1826-1865). Eur Neurol 2013; 70 (5-6): 281-290
    CrossrefPubMedGoogle Scholar
  • 2 Hughes RAC, Cornblath DR, Willison HJ. Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl. Brain 2016; 139 (11) 3041-3047
    CrossrefPubMedGoogle Scholar
  • 3 McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009; 32 (02) 150-163
    CrossrefPubMedGoogle Scholar
  • 4 Liou LS, Chung CH, Wu YT. , et al. Epidemiology and prognostic factors of inpatient mortality of Guillain-Barré syndrome: a nationwide population study over 14years in Asian country. J Neurol Sci 2016; 369: 159-164
    CrossrefPubMedGoogle Scholar
  • 5 Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36 (02) 123-133
    CrossrefPubMedGoogle Scholar
  • 6 Webb AJ, Brain SA, Wood R, Rinaldi S, Turner MR. Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry 2015; 86 (11) 1196-1201
    CrossrefPubMedGoogle Scholar
  • 7 Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry 2013; 84 (05) 576-583
    CrossrefPubMedGoogle Scholar
  • 8 Hosokawa T, Nakajima H, Unoda K. , et al. Serial electrophysiological findings in Guillain-Barré syndrome not fulfilling AIDP or AMAN criteria. J Neurol 2016; 263 (09) 1709-1718
    CrossrefPubMedGoogle Scholar
  • 9 Mishu B, Ilyas AA, Koski CL. , et al. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barré syndrome. Ann Intern Med 1993; 118 (12) 947-953
    PubMedGoogle Scholar
  • 10 Kuroki S, Saida T, Nukina M. , et al. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. Ann Neurol 1993; 33 (03) 243-247
    PubMedGoogle Scholar
  • 11 Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000; 48 (04) 624-631
    CrossrefPubMedGoogle Scholar
  • 12 Griffin JW, Li CY, Ho TW. , et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996; 39 (01) 17-28
    CrossrefPubMedGoogle Scholar
  • 13 Meyer Sauteur PM, Huizinga R, Tio-Gillen AP. , et al. Mycoplasma pneumoniae triggering the Guillain-Barré syndrome: a case-control study. Ann Neurol 2016; 80 (04) 566-580
    CrossrefPubMedGoogle Scholar
  • 14 Hadden RD, Karch H, Hartung HP. , et al; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001; 56 (06) 758-765
    CrossrefPubMedGoogle Scholar
  • 15 Salim OJ, Davidson A, Li K, Leach JP, Heath C. Brainstem encephalitis and acute polyneuropathy associated with hepatitis E infection. BMJ Case Reports. 2017 ;2017
    PubMedGoogle Scholar
  • 16 Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 1984; 119 (06) 841-879
    CrossrefPubMedGoogle Scholar
  • 17 Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ. , et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol 1979; 110 (02) 105-123
    CrossrefPubMedGoogle Scholar
  • 18 Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis 2014; 58 (08) 1149-1155
    CrossrefPubMedGoogle Scholar
  • 19 Nascimento OJM, da Silva IRF. Guillain-Barré syndrome and Zika virus outbreaks. Curr Opin Neurol 2017; 30 (05) 500-507
    CrossrefPubMedGoogle Scholar
  • 20 The Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. Brain 1996; 119 (Pt 6): 2053-2061
    CrossrefPubMedGoogle Scholar
  • 21 May SE, Caudle MR, Kleinman GE. Landry-Guillain-Barré-Strohl syndrome in pregnancy. A report of two cases. J Reprod Med 1989; 34 (08) 550-552
    PubMedGoogle Scholar
  • 22 Ubogu EE, Zaidat OO, Suarez JI. Acute motor-sensory axonal neuropathy associated with active systemic lupus erythematosus and anticardiolipin antibodies. J Clin Rheumatol 2001; 7 (05) 326-331
    CrossrefPubMedGoogle Scholar
  • 23 Hafer-Macko C, Hsieh ST, Li CY. , et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996; 40 (04) 635-644
    CrossrefPubMedGoogle Scholar
  • 24 Yuki N, Taki T, Inagaki F. , et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993; 178 (05) 1771-1775
    CrossrefPubMedGoogle Scholar
  • 25 Takigawa T, Yasuda H, Kikkawa R, Shigeta Y, Saida T, Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Neurol 1995; 37 (04) 436-442
    CrossrefPubMedGoogle Scholar
  • 26 Susuki K, Baba H, Tohyama K. , et al. Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia 2007; 55 (07) 746-757
    CrossrefPubMedGoogle Scholar
  • 27 McGonigal R, Rowan EG, Greenshields KN. , et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 2010; 133 (Pt 7): 1944-1960
    CrossrefPubMedGoogle Scholar
  • 28 Yuki N, Kuwabara S, Koga M, Hirata K. Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile. J Neurol Sci 1999; 168 (02) 121-126
    CrossrefPubMedGoogle Scholar
  • 29 Fan C, Jin H, Hao H. , et al. Anti-ganglioside antibodies in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy in Chinese patients. Muscle Nerve 2017; 55 (04) 470-475
    CrossrefPubMedGoogle Scholar
  • 30 Sawai S, Satoh M, Mori M. , et al. Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. Neurology 2014; 83 (02) 113-117
    CrossrefPubMedGoogle Scholar
  • 31 Kawamura N, Yamasaki R, Yonekawa T. , et al. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 2013; 81 (08) 714-722
    CrossrefPubMedGoogle Scholar
  • 32 Ziganshin RH, Ivanova OM, Lomakin YA. , et al. The pathogenesis of the demyelinating form of Guillain-Barre syndrome (GBS): proteo-peptidomic and immunological profiling of physiological fluids. Mol Cell Proteomics 2016; 15 (07) 2366-2378
    CrossrefPubMedGoogle Scholar
  • 33 Yuki N, Taki T, Takahashi M. , et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994; 36 (05) 791-793
    CrossrefPubMedGoogle Scholar
  • 34 Houliston RS, Koga M, Li J. , et al. A Haemophilus influenzae strain associated with Fisher syndrome expresses a novel disialylated ganglioside mimic. Biochemistry 2007; 46 (27) 8164-8171
    CrossrefPubMedGoogle Scholar
  • 35 Yoshikawa K, Kuwahara M, Morikawa M. , et al. Varied antibody reactivities and clinical relevance in anti-GQ1b antibody-related diseases. Neurol Neuroimmunol Neuroinflamm 2018; 5 (06) e501
    CrossrefPubMedGoogle Scholar
  • 36 Kusunoki S, Chiba A, Kanazawa I. Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 1999; 22 (08) 1071-1074
    CrossrefPubMedGoogle Scholar
  • 37 Liu JX, Willison HJ, Pedrosa-Domellöf F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 2009; 50 (07) 3226-3232
    CrossrefPubMedGoogle Scholar
  • 38 Fukami Y, Wong AH, Funakoshi K, Safri AY, Shahrizaila N, Yuki N. Anti-GQ1b antibody syndrome: anti-ganglioside complex reactivity determines clinical spectrum. Eur J Neurol 2016; 23 (02) 320-326
    CrossrefPubMedGoogle Scholar
  • 39 Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 2014; 137 (Pt 1): 33-43
    CrossrefPubMedGoogle Scholar
  • 40 Wang Y, Shang P, Xin M, Bai J, Zhou C, Zhang HL. The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study. BMC Neurol 2017; 17 (01) 200
    CrossrefPubMedGoogle Scholar
  • 41 Anandan C, Khuder SA, Koffman BM. Prevalence of autonomic dysfunction in hospitalized patients with Guillain-Barré syndrome. Muscle Nerve 2017; 56 (02) 331-333
    CrossrefPubMedGoogle Scholar
  • 42 Bhargava A, Banakar BF, Pujar GS, Khichar S. A study of Guillain-Barré syndrome with reference to cranial neuropathy and its prognostic implication. J Neurosci Rural Pract 2014; 5 (Suppl. 01) S43-S47
    PubMedGoogle Scholar
  • 43 Hadden RD, Cornblath DR, Hughes RA. , et al; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998; 44 (05) 780-788
    CrossrefPubMedGoogle Scholar
  • 44 Ho TW, Mishu B, Li CY. , et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995; 118 (Pt 3): 597-605
    CrossrefPubMedGoogle Scholar
  • 45 Shrivastava M, Nehal S, Seema N. Guillain-Barre syndrome: demographics, clinical profile & seasonal variation in a tertiary care centre of central India. Indian J Med Res 2017; 145 (02) 203-208
    PubMedGoogle Scholar
  • 46 Mitsui Y, Kusunoki S, Arimura K. , et al; Japanese GBS Study Group. A multicentre prospective study of Guillain-Barré syndrome in Japan: a focus on the incidence of subtypes. J Neurol Neurosurg Psychiatry 2015; 86 (01) 110-114
    CrossrefPubMedGoogle Scholar
  • 47 Doets AY, Verboon C, van den Berg B. , et al; IGOS Consortium. Regional variation of Guillain-Barré syndrome. Brain 2018; 141 (10) 2866-2877
    CrossrefPubMedGoogle Scholar
  • 48 McKhann GM, Cornblath DR, Griffin JW. , et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993; 33 (04) 333-342
    CrossrefPubMedGoogle Scholar
  • 49 Capasso M, Notturno F, Manzoli C, Uncini A. Involvement of sensory fibres in axonal subtypes of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2011; 82 (06) 664-670
    CrossrefPubMedGoogle Scholar
  • 50 Islam Z, Jacobs BC, van Belkum A. , et al. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology 2010; 74 (07) 581-587
    CrossrefPubMedGoogle Scholar
  • 51 Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255 (02) 57-65
    CrossrefPubMedGoogle Scholar
  • 52 Bickerstaff ER. Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis. BMJ 1957; 1 (5032): 1384-1387
    CrossrefPubMedGoogle Scholar
  • 53 Wakerley BR, Uncini A, Yuki N. ; GBS Classification Group; GBS Classification Group. Guillain-Barré and Miller Fisher syndromes--new diagnostic classification. Nat Rev Neurol 2014; 10 (09) 537-544
    CrossrefPubMedGoogle Scholar
  • 54 Goodfellow JA, Willison HJ. Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. Curr Opin Neurol 2016; 29 (05) 572-580
    CrossrefPubMedGoogle Scholar
  • 55 Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 2001; 58 (06) 913-917
    CrossrefPubMedGoogle Scholar
  • 56 Albertí MA, Alentorn A, Martínez-Yelamos S. , et al. Very early electrodiagnostic findings in Guillain-Barré syndrome. J Peripher Nerv Syst 2011; 16 (02) 136-142
    CrossrefPubMedGoogle Scholar
  • 57 Uncini A, Ippoliti L, Shahrizaila N, Sekiguchi Y, Kuwabara S. Optimizing the electrodiagnostic accuracy in Guillain-Barré syndrome subtypes: criteria sets and sparse linear discriminant analysis. Clin Neurophysiol 2017; 128 (07) 1176-1183
    CrossrefPubMedGoogle Scholar
  • 58 Rajabally YA, Durand MC, Mitchell J, Orlikowski D, Nicolas G. Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice?. J Neurol Neurosurg Psychiatry 2015; 86 (01) 115-119
    CrossrefPubMedGoogle Scholar
  • 59 Uncini A, Kuwabara S. The electrodiagnosis of Guillain-Barré syndrome subtypes: where do we stand?. Clin Neurophysiol 2018; 129 (12) 2586-2593
    CrossrefPubMedGoogle Scholar
  • 60 Kuwabara S, Yuki N, Koga M. , et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 1998; 44 (02) 202-208
    CrossrefPubMedGoogle Scholar
  • 61 Kuwabara S, Ogawara K, Misawa S. , et al. Sensory nerve conduction in demyelinating and axonal Guillain-Barré syndromes. Eur Neurol 2004; 51 (04) 196-198
    CrossrefPubMedGoogle Scholar
  • 62 Byun WM, Park WK, Park BH, Ahn SH, Hwang MS, Chang JC. Guillain-Barré syndrome: MR imaging findings of the spine in eight patients. Radiology 1998; 208 (01) 137-141
    CrossrefPubMedGoogle Scholar
  • 63 Mulkey SB, Glasier CM, El-Nabbout B. , et al. Nerve root enhancement on spinal MRI in pediatric Guillain-Barré syndrome. Pediatr Neurol 2010; 43 (04) 263-269
    CrossrefPubMedGoogle Scholar
  • 64 Yardimci N, Avci AY, Kayhan E, Benli S. Bilateral facial nerve enhancement demonstrated by magnetic resonance imaging in Guillain-Barré syndrome. Neurol Sci 2009; 30 (05) 431-433
    CrossrefPubMedGoogle Scholar
  • 65 Grimm A, Décard BF, Axer H. Ultrasonography of the peripheral nervous system in the early stage of Guillain-Barré syndrome. J Peripher Nerv Syst 2014; 19 (03) 234-241
    CrossrefPubMedGoogle Scholar
  • 66 Razali SNO, Arumugam T, Yuki N, Rozalli FI, Goh KJ, Shahrizaila N. Serial peripheral nerve ultrasound in Guillain-Barré syndrome. Clin Neurophysiol 2016; 127 (02) 1652-1656
    CrossrefPubMedGoogle Scholar
  • 67 Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry 1998; 64 (01) 74-77
    CrossrefPubMedGoogle Scholar
  • 68 Walgaard C, Lingsma HF, Ruts L. , et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 2010; 67 (06) 781-787
    PubMedGoogle Scholar
  • 69 Ruts L, Drenthen J, Jongen JL. , et al; Dutch GBS Study Group. Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology 2010; 75 (16) 1439-1447
    CrossrefPubMedGoogle Scholar
  • 70 Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barré syndrome. Cochrane Database Syst Rev 2015; (04) CD009950
    PubMedGoogle Scholar
  • 71 Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2017; 2: CD001798
    PubMedGoogle Scholar
  • 72 Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014; (09) CD002063
    PubMedGoogle Scholar
  • 73 van der Meché FG, Schmitz PI. ; Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326 (17) 1123-1129
    CrossrefPubMedGoogle Scholar
  • 74 Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349 (9047): 225-230
    CrossrefPubMedGoogle Scholar
  • 75 Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2016; 10: CD001446
    PubMedGoogle Scholar
  • 76 Misawa S, Kuwabara S, Sato Y. , et al; Japanese Eculizumab Trial for GBS (JET-GBS) Study Group. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol 2018; 17 (06) 519-529
    CrossrefPubMedGoogle Scholar
  • 77 Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, Cornblath DR, van Doorn PA. Second IVIg course in Guillain-Barre syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial. J Peripher Nerv Syst 2018; 23 (04) 210-215
    CrossrefPubMedGoogle Scholar